leukemias	are	blood cancers
leukemias	arise from	hematopoietic cells
ALL	is a subtype of	leukemia
AML	is a subtype of	leukemia
CLL	is a subtype of	leukemia
CML	is a subtype of	leukemia
hairy cell leukemia	is a subtype of	leukemia
Philadelphia chromosome	is a marker for	CML
BCR-ABL1 fusion	is a hallmark of	CML
PML-RARA fusion	is a hallmark of	APL
APL	is a subtype of	AML
cytogenetic abnormalities	are common in	leukemia
t(15;17)	is a cytogenetic abnormality	APL
PML-RARA fusion	is a cytogenetic abnormality	APL
TP53 mutation	is associated with	poor prognosis in leukemia
NPM1 mutation	is associated with	AML prognosis
FLT3 mutation	is associated with	AML prognosis
minimal residual disease	is used for	prognosis
minimal residual disease	predicts	relapse
complete remission	is a goal of	induction therapy
induction chemotherapy	achieves	remission
cytarabine	is used for	AML
daunorubicin	is used for	AML
idarubicin	is used for	AML
7+3 chemotherapy	is standard induction for	AML
ATRA	is used for	APL
arsenic trioxide	is used for	APL
imatinib	is used for	CML
dasatinib	is used for	CML
nilotinib	is used for	CML
ponatinib	is used for	CML
bosutinib	is used for	CML
tyrosine kinase inhibitors	are used for	CML
allogeneic stem cell transplant	provides	graft-versus-leukemia effect
allogeneic stem cell transplant	reduces	relapse
autologous stem cell transplant	used for	relapsed leukemia
benzene exposure	increases risk of	leukemia
ionizing radiation	increases risk of	leukemia
therapy-related leukemia	is a type of	leukemia
age	influences	prognosis
cytogenetics	influences	prognosis
splenomegaly	occurs in	CML
lymphadenopathy	occurs in	CLL
bone marrow failure	results in	cytopenias
cytopenias	cause	fatigue
anemia	is common in	leukemia
thrombocytopenia	is common in	leukemia
infections	risk in	leukemia
fever	is a symptom of	leukemia
fatigue	is a symptom of	leukemia
bone pain	is a symptom of	ALL
CNS involvement	worsens prognosis in	leukemia
intrathecal chemotherapy	is used for	CNS prophylaxis
CNS prophylaxis	is used for	ALL
intrathecal methotrexate	is used for	CNS prophylaxis
prednisone	is used for	ALL
vincristine	is used for	ALL
L-asparaginase	is used for	ALL
rituximab	is used for	CLL
ibrutinib	is used for	CLL
venetoclax	is used for	CLL
granulocyte colony-stimulating factor	is used for	supportive care in leukemia
transfusion	is used for	severe anemia
red blood cell transfusion	is used for	severe anemia
platelet transfusion	is used for	thrombocytopenia
remission	is achieved with	induction chemotherapy
remission	improves	survival
survival	depends on	prognosis
pediatric patients	have	better prognosis
allogeneic transplant	improves	survival
graft-versus-host disease	is a complication of	allogeneic transplant
pharmacogenomics	informs	prognosis in leukemia
FLT3-ITD mutation	is associated with	poor prognosis in AML
RUNX1-RUNX1T1	is a fusion gene	associated with	AML (M2)
t(8;21)	is a cytogenetic abnormality	found in	AML
inv(16)	is a cytogenetic abnormality	found in	AML
t(9;22)	is a cytogenetic abnormality	found in	CML
AML	can present with	anemia
ALL	can present with	bone pain
CLL	presents with	lymphocytosis
relapse	requires	salvage therapy
salvage therapy	includes	high-dose chemotherapy
high-dose chemotherapy	used for	salvage therapy
CR	stands for	complete remission
leukemia stem cells	drive	disease persistence
central nervous system relapse	occurs after	leukemia therapy
immunotherapy	is used for	leukemia
CAR-T cell therapy	is a form of	immunotherapy
ALL	often treated with	pediatric regimens
adult ALL	has	worse prognosis relative to pediatric
CML blast crisis	is a phase of	CML
tyrosine kinase inhibitor resistance	leads to	disease progression
BCR-ABL1	is expressed in	CML
disease-free survival	is a measure of	leukemia outcome
overall survival	is a measure of	leukemia outcome
improved survival	is associated with	early transplant
allogeneic donor	must be	HLA-matched
HLA matching	improves	transplant outcome
AML	treated with	cytarabine-based chemotherapy
APL	managed with	ATRA
APL	managed with	arsenic trioxide
adult ALL	responds to	vincristine
CAR-T cell therapy	requires	lymphodepletion
CR	indicates	remission
remission duration	affects	long-term survival
minimal residual disease	negativity	predicts	better survival
hematopoietic stem cell	transplantation	enables	immune reconstitution
neutropenia	predisposes to	infection
neutropenia	duration	affects	infection risk
steroid therapy	reduces	inflammation
steroid therapy	increases	infection risk
immunoglobulin levels	influence	infection risk
platelet count	correlates with	bleeding risk
p53 pathway	influences	cell cycle control
BCL-2 family	regulates	apoptosis
cancer-testis antigen	expressed in	leukemia
hypomethylating agents	used for	myelodysplastic syndrome
myelodysplastic syndrome	predisposes to	leukemia
allogeneic donor	must be	HLA-identical
HLA typing	guides	donor selection
donor chimerism	measures	engraftment
engraftment	indicates	transplant success
CD19 expression	identifies	B-ALL
CD20 expression	identifies	B-ALL
cytoplasmic PAS	used for	leukemia diagnosis
TdT expression	indicates	lymphoblastic leukemia
corticoid response	predicts	ALL prognosis
dexamethasone	used for	ALL
hydroxyurea	used for	cytoreduction in leukemia
cancer vaccination	under investigation for	leukemia
resistance mutations	complicate	targeted therapy in leukemia
ALL relapse	occurs after	initial remission
AML relapse	occurs after	initial remission
